3Esper R, Nordaby R, Vilarino J, et al. Endothelial dysfunction: a comprehensive appraisal [J]. Cardiovasc Diabetol, 2006, 5: 4--21.
4Tzemos N, Lim PO, Macdonald TM. Valsartan improves vascular endothelial dysfunction in essential hypertension: a randomized, double study [J]. Cardiorasc Ther, 2009, 27 (3): 151 --158.
5Scheidegger KJ, Butler S, Witztum JL, et al. Angiotensin 11 increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway [J]. J BiolChem, 1997, 272 (34): 21609--21615.
6Brook RD, Bard RL, Kehrer C, et al. Valsartan improves insulin sensitivity without altering vascular funetion in healthy overweight adults without the metabolic syndrome [J]. Metab Syndr Relat Disord, 2007, 5 (3):255--261.
7Sarzani R, Salvi F, Dessi-Fulgheri P, et al. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension., an integrated view in humans [ J]. J Hypertens, 2008, 26 (5): 831--843.
8Marre M, Leye A. Effects of perindopril in hypertensive patients with or without type 2 diabetes mellitus, and with altered insulin sensitivity [J]. Diab Vasc Dis Res, 2007, 4 (3) : 163-- 173.
9Panza JA, Quyyumi AA, Brush JE, et al. Abnormal endothelium dependent vascular relaxation in patients with essential hypertension [J]. N Engl J Med, 1990, 323: 22--27.
10Nakagawa T, Kang DH, Feig D, et al. Unearthing uric acid: an ancient factor with recently found significance in renal and cardiovascular disease [J]. Kidney Int, 2006, 69:1722--1725.
